Crestline Management’s Nektar Therapeutics NKTR Stock Holding History

Crestline Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-702	Closed	-$247K	–	161
2017 Q1	$247K	Buy	+702	New	+$158K	0.05%	106

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Crestline Management's NKTR Position: Q2 2017 in Review

Crestline Management sold out of Nektar Therapeutics (NKTR) in Q2 2017, closing a stake of 702 shares — an estimated $247K sold.

Crestline Management first reported a position in NKTR in Q1 2017 and held it in 1 quarter. The position peaked at $247K in Q1 2017. 197 funds tracked by Wall St. Rank hold NKTR as of Q2 2017.

Crestline Management reported no remaining Nektar Therapeutics position as of Q2 2017 after selling out during the quarter.
Crestline Management sold 702 Nektar Therapeutics shares in Q2 2017, an estimated $247K.
Crestline Management first reported a position in Nektar Therapeutics in Q1 2017 and held it in 1 quarter.
Crestline Management's Nektar Therapeutics position peaked at $247K in Q1 2017.
197 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2017.

Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.